Petros Pharmaceuticals In... (PTPI)
Petros Pharmaceuticals Statistics
Share Statistics
Petros Pharmaceuticals has 53.52M shares outstanding. The number of shares has increased by 327.55% in one year.
| Shares Outstanding | 53.52M |
| Shares Change (YoY) | 327.55% |
| Shares Change (QoQ) | 198.85% |
| Owned by Institutions (%) | 3.35% |
| Shares Floating | 43.8M |
| Failed to Deliver (FTD) Shares | 103.87K |
| FTD / Avg. Volume | 0.29% |
Short Selling Information
The latest short interest is 1.48M, so 5.86% of the outstanding shares have been sold short.
| Short Interest | 1.48M |
| Short % of Shares Out | 5.86% |
| Short % of Float | 6.08% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -2.21 and the forward PE ratio is -0.04. Petros Pharmaceuticals's PEG ratio is 0.02.
| PE Ratio | -2.21 |
| Forward PE | -0.04 |
| PS Ratio | 0.01 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | -0.01 |
| PEG Ratio | 0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Petros Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.4, with a Debt / Equity ratio of 0.
| Current Ratio | 0.4 |
| Quick Ratio | 0.33 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -31519.64 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $284M |
| Profits Per Employee | $-795.49K |
| Employee Count | 18 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 0.9 |
Taxes
| Income Tax | 12.48B |
| Effective Tax Rate | -87.15% |
Stock Price Statistics
The stock price has increased by -92.19% in the last 52 weeks. The beta is 2.09, so Petros Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 2.09 |
| 52-Week Price Change | -92.19% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 42.74 |
| Average Volume (20 Days) | 36.11M |
Income Statement
In the last 12 months, Petros Pharmaceuticals had revenue of 5.11B and earned -14.32M in profits. Earnings per share was -0.02.
| Revenue | 5.11B |
| Gross Profit | 3.9B |
| Operating Income | -17.68B |
| Net Income | -14.32M |
| EBITDA | -12.05B |
| EBIT | -14.88B |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
The company has 3.71M in cash and 7.39M in debt, giving a net cash position of -3.68M.
| Cash & Cash Equivalents | 3.71M |
| Total Debt | 7.39M |
| Net Cash | -3.68M |
| Retained Earnings | -113.21B |
| Total Assets | 10.64M |
| Working Capital | -10.73M |
Cash Flow
In the last 12 months, operating cash flow was -2.6B and capital expenditures 0, giving a free cash flow of -2.6B.
| Operating Cash Flow | -2.6B |
| Capital Expenditures | 0 |
| Free Cash Flow | -2.6B |
| FCF Per Share | -32.43 |
Margins
Gross margin is 76.28%, with operating and profit margins of -345.84% and -0.28%.
| Gross Margin | 76.28% |
| Operating Margin | -345.84% |
| Pretax Margin | -280.1% |
| Profit Margin | -0.28% |
| EBITDA Margin | -235.69% |
| EBIT Margin | -345.84% |
| FCF Margin | -50.92% |
Dividends & Yields
PTPI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for PTPI.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 1, 2022. It was a backward split with a ratio of 1:10.
| Last Split Date | Dec 1, 2022 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -19.81 |
| Piotroski F-Score | 4 |